Pyxis Oncology (PYXS) Cash & Equivalents (2020 - 2026)

Pyxis Oncology (PYXS) has reported Cash & Equivalents for 6 consecutive years, with $15.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents fell 20.8% year-over-year to $15.4 million; the TTM figure through Dec 2025 stood at $15.4 million (down 20.8% YoY), while the FY2025 annual figure was $15.4 million, down 20.8% from the prior year.
• Cash & Equivalents grew to $15.4 million in Q4 2025 per PYXS's latest filing, from $8.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $274.7 million in Q4 2021 and bottomed at $8.9 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $88.8 million across 5 years, with a median of $26.9 million in 2023.
• Annual changes were most pronounced in 2021 — Cash & Equivalents soared 1086.88% — and 2023, when it plunged 94.61%.
• Pyxis Oncology's Cash & Equivalents stood at $274.7 million in 2021, then slumped by 34.74% to $179.3 million in 2022, then slumped by 94.61% to $9.7 million in 2023, then soared by 101.5% to $19.5 million in 2024, then dropped by 20.8% to $15.4 million in 2025.
• Business Quant data shows PYXS's Cash & Equivalents at $15.4 million in Q4 2025, $8.9 million in Q3 2025, and $10.7 million in Q2 2025.